# PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.

> **NCT01685333** · PHASE1 · COMPLETED · sponsor: **Azidus Brasil** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT01685333
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2013-10-31
- **Final completion:** 2013-10-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685333, "PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01685333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*